Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial

Schizophrenia Research

Volumn 153, Issue 1-3, 2014, Pages 169-176

  Liu, Fang ^a,b   Guo, Xiaofeng ^a   Wu, Rengrong ^a   Ou, Jianjun ^a   Zheng, Yingjun ^a   Zhang, Bingkui ^b   Xie, Liqin ^b   Zhang, Limei ^c   Yang, Li ^c   Yang, Shuyun ^c   Yang, Junwei ^c   Ruan, Ye ^c   Zeng, Yong ^b   Xu, Xiufeng ^b   Zhao, Jingping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c Mental Health Centre of Yunnan Province   (China)

Author keywords

Cognition; Minocycline; Negative symptom; Schizophrenia

Indexed keywords

MINOCYCLINE; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; SCORING SYSTEM; URINARY HESITANCY; WEIGHT GAIN; XEROSTOMIA; ANALYSIS OF VARIANCE; COGNITION DISORDERS; COMPLICATION; FOLLOW UP; HYPERKINESIS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERKINESIS; MALE; MINOCYCLINE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84895818899     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.01.011     Document Type: Article

References (45)

1. Ahn K.H., Youn T., Cho S.S., Ha T.H., Ha K.S., Kim M.S., Kwon J.S. N-methyl-d-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(6):993-999.
2. Alvarez-Jiménez M., González-Blanch C., Vázquez-Barquero J.L., Pérez-Iglesias R., Martínez-García O., Pérez-Pardal T., Ramírez-Bonilla M.L., Crespo-Facorro B. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J. Clin. Psychiatry 2006, 67(8):1253-1260.
3. Amitai N., Markou A. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-d-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol. Psychiatry 2010, 68(1):5-16.
4. Barnes T.R. The Barnes Akathisia Rating Scale - revisited. J. Psychopharmacol. 2003, 17(4):365-370.
5. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76(2):77-98.
6. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8(1):57-69.
7. Blum D., Chtarto A., Tenenbaum L., Brotchi J., Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 2004, 17(3):359-366.
8. Bohnen N.I., Kuwabara H., Constantine G.M., Mathis C.A., Moore R.Y. Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci. Lett. 2007, 424(3):185-189.
9. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26(9):1185-1193.
10. Chaves C., Marque C.R., Trzesniak C., Machado de Sousa J.P., Zuardi A.W., Crippa J.A., Dursun S.M., Hallak J.E. Glutamate-N-methyl-d-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz. J. Med. Biol. Res. 2009, 42(11):1002-1014.
11. Chaves C., de Marque C.R., Wichert-Ana L., Maia-de-Oliveira J.P., Itikawa E.N., Crippa J.A., Zuardi A.W., Todd K.G., Baker G.B., Dursun S.M., Hallak J.E. Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(3):550-552.
12. Converse A.K., Larsen E.C., Engle J.W., Barnhart T.E., Nickles R.J., Duncan I.D. 11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. J. Nucl. Med. 2011, 52(2):257-262.
13. DeLegge M.H., Smoke A. Neurodegeneration and inflammation. Nutr. Clin. Pract. 2008, 23(1):35-41.
14. Dobrek L., Thor P. Glutamate NMDA receptors in pathophysiology and pharmacotherapy of selected nervous system diseases. Postepy Hig. Med. Dosw. (Online) 2011, 65:338-346.
15. Filipovic R., Zecevic N. Neuroprotective role of minocycline in co-cultures of human fetal neurons and microglia. Exp. Neurol. 2008, 211(1):41-51.
16. Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(2):336-339.
17. Golden C.J. The measurement of creativity by the Stroop Color and Word Test. J. Pers. Assess. 1975, 39(5):502-506.
18. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH - MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 2004, 56(5):301-307.
19. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10(11):1387-1394.
20. Hanson E., Healey K., Wolf D., Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr. Psychiatry Rep. 2010, 12(6):563-571.
21. Imbesi M., Uz T., Manev R., Sharma R.P., Manev H. Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci. Lett. 2008, 447(2):134-137.
22. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 2010, 83(3-4):108-121.
23. Kelly D.L., Vyas G., Richardson C.M., Koola M., McMahon R.P., Buchanan R.W., Wehring H.J. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr. Res. 2011, 133(1-3):257-258.
24. Kim S.S., Kong P.J., Kim B.S., Sheen D.H., Nam S.Y., Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch. Pharm. Res. 2004, 27(3):314-318.
25. Kuriyama K., Honma M., Shimazaki M., Horie M., Yoshiike T., Koyama S., Kim Y. An N-methyl-d-aspartate receptor agonist facilitates sleep-independent synaptic plasticity associated with working memory capacity enhancement. Sci. Rep. 2011, 1:127.
26. Lee S.M., Yune T.Y., Kim S.J., Kim Y.C., Oh Y.J., Markelonis G.J., Oh T.H. Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J. Neurochem. 2004, 91(3):568-578.
27. Levkovitz Y., Levi U., Braw Y., Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007, 1154:154-162.
28. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., Treves I., Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71(2):138.
29. Luck S.J., Gold J.M. The construct of attention in schizophrenia. Biol. Psychiatry 2008, 64(1):34-39.
30. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin. Neuropharmacol. 2008, 31(5):287-292.
31. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63(3):257-265.
32. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42(5):115-121.
33. Raja M. Pharmacotherapy update: risperidone in the treatment of schizophrenia. Clin. Med. Ther. 2009, 1:1199-1214.
34. Schwartz T.L., Sachdeva S., Stahl S.M. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front. Pharmacol. 2012, 3.
35. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
36. Smith R.C., Lindenmayer J.P., Bark N., Warner-Cohen J., Vaidhyanathaswamy S., Khandat A. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int. J. Neuropsychophharmacol 2005, 8(2):183-194.
37. Sofuoglu M., Mooney M., Kosten T., Waters A., Hashimoto K. Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology (Berl.) 2011, 213(1):61-68.
38. Steiner J., Bogerts B., Sarnyai Z., Walter M., Gos T., Bernstein H.-G., Myint A.-M. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J. Biol. Psychiatry 2012, 13(7):482-492.
39. Tien A.Y., Spevack T.V., Jones D.W., Pearlson G.D., Schlaepfer T.E., Strauss M.E. Computerized Wisconsin Card Sorting Test: comparison with manual administration. Kaohsiung J. Med. Sci. 1996, 12(8):479-485.
40. Tikka T., Fiebich B.L., Goldsteins G., Keinänen R., Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 2001, 21(8):2580-2588.
41. Wahlbeck K., Tuunainen A., Ahokas A., Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl.) 2001, 155(3):230-233.
42. Watabe M., Kato T.A., Monji A., Horikawa H., Kanba S. Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction?. Psychopharmacology (Berl.) 2012, 220(3):551-557.
43. Wu R.R., Jin H., Gao K., Twamley E.W., Ou J.J., Shao P., Wang J., Guo X.F., Davis J.M., Chan P.K., Zhao J.P. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 2012, 169(8):813-821.
44. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 2011, 25(2):181-213.
45. Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32(9):2004-2010.